Fuller & Thaler Asset Management
BMRN icon

Fuller & Thaler Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fuller & Thaler Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-890,418
Closed -$48.2M – 504
2025
Q3 		$48.2M Sell
890,418
-7,098
-0.8% -$406K 0.16% 200
2025
Q2 		$49.3M Buy
897,516
+61,119
+7% +$3.6M 0.18% 189
2025
Q1 		$59.1M Buy
+836,397
New +$56.3M 0.23% 157

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fuller & Thaler Asset Management's BMRN Position: Q4 2025 in Review

Fuller & Thaler Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 890,418 shares — an estimated $48.2M sold.

Fuller & Thaler Asset Management first reported a position in BMRN in Q1 2025 and held it in 3 quarters. The position peaked at $59.1M in Q1 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Fuller & Thaler Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 890,418 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $48.2M.
  • Fuller & Thaler Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Fuller & Thaler Asset Management's BioMarin Pharmaceuticals position peaked at $59.1M in Q1 2025.
  • 539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Fuller & Thaler Asset Management's 13F filing for Q4 2025, filed 12 Feb 2026.